Antioxidants (Apr 2022)

Mercaptoalbumin Is Associated with Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting

  • Maura Brioschi,
  • Erica Gianazza,
  • Daniele Andreini,
  • Saima Mushtaq,
  • Laura Cavallotti,
  • Fabrizio Veglia,
  • Calogero C. Tedesco,
  • Gualtiero I. Colombo,
  • Mauro Pepi,
  • Gianluca Polvani,
  • Elena Tremoli,
  • Alessandro Parolari,
  • Cristina Banfi

DOI
https://doi.org/10.3390/antiox11040702
Journal volume & issue
Vol. 11, no. 4
p. 702

Abstract

Read online

Coronary artery bypass graft (CABG) surgery still represents the gold standard for patients with complex multivessel coronary artery disease. However, graft occlusion still occurs in a significant proportion of CABG conduits, and oxidative stress is currently considered to be a potential contributor. Human serum albumin (HSA) represents the main antioxidant in plasma through its reduced amino acid Cys34, which can efficiently scavenge several oxidants. In a nested case–control study including 36 patients with occluded grafts and 38 age- and sex-matched patients without occlusion, we assessed the levels of the native mercaptoalbumin (HSA-SH) and oxidized thiolated form of albumin (Thio-HSA) in relation with graft occlusion within 5 years after CABG. We found that the plasma level of preoperative HSA-SH was significantly lower in patients with occluded graft at 5 years follow-up than in patients with graft patency. Furthermore, low HSA-SH remained independently associated with graft occlusion even after adjusting for preoperative D-dimer, a well-known marker of activated coagulation recently found to be associated with graft occlusion. In conclusion, the preoperative level of HSA-SH is independently associated with graft occlusion in CABG and represents a measurable and potentially druggable predictor.

Keywords